Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources by Kao, Chung-Feng et al.
Prioritization and Evaluation of Depression Candidate
Genes by Combining Multidimensional Data Resources
Chung-Feng Kao
1, Yu-Sheng Fang
2, Zhongming Zhao
3, Po-Hsiu Kuo
1,2,4*
1Department of Public Health and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, 2Institute of
Clinical Medicine, School of Medicine, National Cheng-Kung University, Tainan, Taiwan, 3Departments of Biomedical Informatics and Psychiatry, Vanderbilt University
School of Medicine, Nashville, Tennessee, United States of America, 4Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei,
Taiwan
Abstract
Background: Large scale and individual genetic studies have suggested numerous susceptible genes for depression in the
past decade without conclusive results. There is a strong need to review and integrate multi-dimensional data for follow up
validation. The present study aimed to apply prioritization procedures to build-up an evidence-based candidate genes
dataset for depression.
Methods: Depression candidate genes were collected in human and animal studies across various data resources. Each
gene was scored according to its magnitude of evidence related to depression and was multiplied by a source-specific
weight to form a combined score measure. All genes were evaluated through a prioritization system to obtain an optimal
weight matrix to rank their relative importance with depression using the combined scores. The resulting candidate gene
list for depression (DEPgenes) was further evaluated by a genome-wide association (GWA) dataset and microarray gene
expression in human tissues.
Results: A total of 5,055 candidate genes (4,850 genes from human and 387 genes from animal studies with 182 being
overlapped) were included from seven data sources. Through the prioritization procedures, we identified 169 DEPgenes,
which exhibited high chance to be associated with depression in GWA dataset (Wilcoxon rank-sum test, p=0.00005).
Additionally, the DEPgenes had a higher percentage to express in human brain or nerve related tissues than non-DEPgenes,
supporting the neurotransmitter and neuroplasticity theories in depression.
Conclusions: With comprehensive data collection and curation and an application of integrative approach, we successfully
generated DEPgenes through an effective gene prioritization system. The prioritized DEPgenes are promising for future
biological experiments or replication efforts to discoverthe underlying molecular mechanisms for depression.
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Introduction
Major depressive disorder (MDD) is a complex disorder with
high prevalence and is the fourth leading cause of disease burden
worldwide [1]. The lifetime prevalence of depression ranges from
9.2 to19.6% worldwide [2–4], and heritability is estimated at
approximately 37–43% [5]. Over the last decade, many studies
have been devoted to dissecting the genetic influences of
depression using a variety of experimental designs and technolog-
ical approaches, including genomic-wide linkage scans, genetic
association studies, and microarray gene expression [6–12].
Several hypotheses have been proposed for the biological
mechanisms of developing depression based on prior evidence
[13–16], including monoamine-deficiency hypothesis, hypothalamic-pitui-
tary-cortisol hypothesis and other possible pathophysiological mech-
anisms (e.g. neurogenesis, abnormal circadian rhythms). Most
recently, genome-wide association (GWA) studies have been
applied to search for common susceptible variants and genes in
several thousands of samples, in turn generating new hypotheses
for the biological mechanisms of depression [7,9,10,17]. Massive
amounts of genetic data from numerous studies and sources have
been accumulated rapidly. Moreover, combining genetic infor-
mation in the regulatory pathway takes advantage of additional
biological knowledge that is not directly available from traditional
genetic studies. Results from each study are influenced by different
study designs, analytic strategies, ethnic populations, and sample
sizes. Thus, integrating depression genetic data and information
from individual studies, literature review, and biological pathways
in multiple resources may provide us list of evidence-based
candidate genes for future experimental validation. Such effort has
recently been shown in the study of other complex diseases but has
not been applied to depression yet.
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studies is meta-analysis, which usually requires data generated by
the same design. Findings from various study designs and data
sources made it impractical to combine data directly using
rigorous statistical testing. Therefore, an alternative powerful
integration strategy is needed to combine genetic data from
different study settings and across species. Specifically, in
neuropsychiatric genetics, several approaches have been devel-
oped and applied to integrate genetic data for schizophrenia and
Alzheimer’s disease. Ma et al. [18] prioritized genes by combining
gene expression and protein-protein interaction data for Alzhei-
mer’s disease. Sun et al. [19] integrated multi-source genetic data
for schizophrenia by a data integration and weighting framework
in which the strength of evidence in different data categories is
considered and combined by appropriate weights. This approach
can be applied to other complex diseases where multi-dimensional
data is available. For some complex traits, efforts have been made
to integrate and organize data for better utilizing prior research
findings, such as a comprehensive and regularly updated
Schizophrenia Gene database (Schizophrenia Research Forum,
http://www.szgene.org/), an Ethanol Related Gene Resource
(ERGR) [20], and a review on the Human Obesity Gene Map for
diabetes [21]. In comparison, the progress of identifying biological
mechanisms, drug development, and strategies for effective
prevention and intervention in response to depression has been
relatively slow [22,23].
Similar to other psychiatric traits, very few significant variants
were found from GWA studies due to small effect size [24] in
depression, while many more candidate genes were examined in
individual genetic studies with inconclusive results. Additional
important genetic findings for depression were also derived from
mouse models. In the present study, we applied and modified the
approach of Sun et al. [19] to effectively integrate multi-
dimensional resources of genetic data in both human and mouse
studies. We aimed to build up an evidence-based candidate gene
framework for depression and used a gene prioritization system to
select a final set of depression genes (DEPgenes). We then
evaluated the performance of prioritization of DEPgenes by
examining the enrichment of small p-values in DEPgenes using a
depression GWA dataset and gene expression pattern in human
tissues. Our evaluation suggests that our evidence-based DEPgenes
might serve as a useful and promising gene source for investigators
to further explore the underlying pathophysiology and biological
mechanisms for depression.
Materials and Methods
2.1 Candidate genes collection and scoring system
Genetic data was collected from five data sources in human
studies and two in animal studies, including association studies,
linkage scans, gene expression (both human and animal studies),
literature search (both human and animal studies), and biological
regulatory pathways. We described the procedures below.
Candidate genes in association studies were searched via
published articles of individual studies and meta-analysis. Lo ´pez-
Leo ´n et al. [25] conducted a meta-analysis for MDD and reviewed
183 genetic association studies prior to June 2007, which reported
125 susceptible genes for depression. Among them, 20 genes had
polymorphisms in at least three studies. We searched genetic
association studies for depression (including binary MDD
diagnosis published after June 2007, and measures of depressive
mood by validated scales) from NCBI PubMed database. We then
manually reviewed them and obtained information on positive or
negative associations. Six depression keywords were used. Other
than ‘depressive disorder’ for binary diagnosis, we included five
quantitative measures: ‘depression symptoms’, ‘Beck depression
inventory’, ‘Hamilton depression rating scale’, ‘center for
epidemiologic studies depression scale’, and ‘neuroticism’. As a
result, we found 141 publications covering 62 genes, all of which
were included in the above 125 susceptible genes list. We noticed
that there might have publication bias in collecting association
data (e.g. 32.8% genes with positive association results only). To
reduce possible impacts of publication bias in the study, we did not
use original significance level for genes in association studies;
instead, we defined a scoring system ranging from 0–4 in an
attempt to account for the lower chance of publishing negative
findings. We applied two criteria to assign a score for each gene:
the total number of studies conducted for a gene and the
proportion of positive results among those studies. It is more likely
to have an extreme proportion of positive results when the total
number of studies related to the gene is small (an extreme
example: only one study conducted for a gene and results showing
positive association, resulting in a proportion of positive results
equaling 1). Hence, we considered both criteria for scoring so the
proportion of positive results would not be largely inflated by non-
published negative findings. Each gene was given a score (noted as
Si) based on a cut-off for the combinations of the two criteria (see
Supplement Table S1 for scoring). A higher score was assigned to
a gene if the total number of studies for that gene was large and the
proportion of positive results was high. As a result, we had 125
genes with the assigned scores ranging from 0 to 4.
Recently, Harvey et al. [1] reviewed published linkage studies
from years 1995 to 2006 regarding mood disorders, and reported
26 genomic regions that showed strong linkage signals to MDD. In
addition, we searched individual genome-wide linkage studies in
the NCBI PubMed database that were published before 2010 and
were not included in Harvey et al. [1] for traits related to affection,
including ‘depressive disorder’, ‘bipolar disorder’ and ‘neuroticism’
to obtain extra linkage regions. Three articles [6,8,12] were found.
Because the resolution in linkage studies was usually low, and it is
not easy to define a confidence interval for each linkage peak
across many linkage studies, to identify candidate genes (using
Ensembl Build 56) in every linkage peak, we arbitrarily defined the
boundaries of each selected region by the position of the markers
giving the highest logarithm of odds (LOD) scores and extending
10 megabases in both directions. This resulted in a total of 3,628
genes in 33 chromosomal regions. These genes were assigned a
score of 1 if their corresponding LOD score ranged between 1 and
2, and the score increased by 1 with an increment of 1 LOD score
unit. A score 0 was assigned if the corresponding LOD score was
less than 1. Some studies only reported p-values; their 2log10p
values were used in such cases. If both LOD and p-values were
reported, scores for genes were decided based on the maximum of
LOD and 2log10p. In this data platform, the assigned scores for
candidate genes ranged from 0 to 4.6.
To collect gene expression data, we used the Stanley Medical
Research Institute online genomics database (SMRIDB). This
database collected 12 individual studies using postmortem human
brain tissues in 988 array-based expression analyses for depression,
schizophrenia and bipolar disorder (https://www.stanleygenomics.
org/, November, 2007) [26]. We downloaded the data from the
SMRIDB for depression and extracted genes whose p-values were
less than 0.05; this resulted in 301 genes scored from 0 to 4.6. Scores
of these genes were assigned by 2log10p. To extend the collection of
expression data, we additionally searched animal studies of gene
expression that examined depression-like behaviors in mice [11].
For these mouse genes, their human homologs were identified by
NCBI HomoloGene database (http://www.ncbi.nlm.nih.gov/
Prioritized Candidate Genes Set for Depression
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expression array were assigned by 2log10p. As a result, we had 252
genes scored from 0 to 5.6.
We also conducted literature searches to identify the relationship
between depression and genes, which may not be seen in other data
sources described above. It is also possible that genes identified by
literature search overlapped with previously identified candidate
genes, particularly in data sources of association and microarray
studies. Literature searches were conducted using the NCBI
PubMed database for the co-occurrence of two entries: a gene
name and a depression related keyword to identify their
relationship. Since some gene names are identical to meaningful
vocabularies (e.g. LARGE, CAT, CLOCK), we used the file
‘‘gene2pubmed’’ downloaded from NCBI-GENE ftp site (ftp://ftp.
ncbi.nlm.nih.gov/gene, June, 2010) to identify gene symbols. Six
terms (depression, depressive disorder, unipolar disorder, dysthy-
mia, major depression and major depressive disorder) were selected
as depression related keywords in human studies. We extracted the
unique identifier for a citation (PubMed identifiers, PMIDs) from
PubMed.Ifa geneanda keywordco-occurredinthesame reference
citation, a hit was identified. Hence, a gene could be scored from 0
(no any hit with depression keywords) to 6 (with all six keywords). In
total, 473 genes were scored in human studies. Using the same
procedure, literature searches were conducted for mouse studies as
well. Six terms related to depressive behaviors in animal models
wereselected,includingforced swimtest,tailsuspensiontest,elevate
plus maze, novelty induced hypophagia, olfactory bulbectomy and
open field test (http://www.natureprotocols.com/2007/12/13/
animal_models_for_depressionli.php) according to a review article
of Hunsberger et al [27]. Similarly, the human homologs of the
mouse genes were identified. As a result, we had 306 genes scored
ranging from 0 to 4.
The collection of genes involved in depression-related pathways
was more subjective. Based on recent review articles [14,23,28]
that summarized regulatory pathways in relation to depression
using evidence from biological, molecular, and cellular mecha-
nisms, we identified genes that correspond to aforementioned
mechanisms, including monoamine-deficiency hypothesis (three
pathways), hypothalamic pituitary adrenal axis (four pathways),
and other possible pathophysiological mechanisms (five pathways);
details please see Supplementary Table S2. Candidate genes were
extracted for the 12 pathways via gene-pathway mapping on
KEGG (the Kyoto Encyclopedia of Genes and Genomes) database
[29,30]. We assigned a score of 3 to genes that are in the pathways
corresponding to the monoamine-deficiency mechanism, a score
of 2 for hypothalamic-pituitary-adrenal axis, and a score of 1 for
other possible mechanisms. If a gene belongs to more than one
mechanism, the greater score was chosen for this gene. We had a
total of 827 genes with scores ranging from 1 to 3.
2.2 Core genes and GWA dataset
In the candidate genes collection step, we obtained 5,055 genes
in total (see Supplementary Table S3). To prioritize these genes
according to existing evidence, we used two datasets—a core gene
set and a depression GWA dataset—to search for the optimal
weights for the seven data sources. Fourteen genes were selected
for the core gene set. Six genes (APOE, DRD4, GNB3, MTHFR,
SLC6A3 and SLC6A4) were based on a meta-analysis for MDD
[25], and 8 genes (BDNF, CREB1, GRM7, HTR1A, HTR1B,
HTR2A, MAOA and TPH1) were selected from other review
articles for MDD [13,22,23]. The GWA data for depression was
downloaded through the Genetic Association Information Net-
work (GAIN) (http://www.ncbi.nlm.nih.gov/sites/entrez?db=
gap). This MDD GWA data included 1,738 depression cases
and 1,802 controls in the Netherlands; a detailed description of
this GWA study was provided in Sullivan et al. [10]. A SNP (single
nucleotide polymorphism) was assigned to a gene if its location was
within the gene or 20kb upstream or downstream of the gene. The
smallest p-value among the SNPs mapped in a gene was chosen to
represent the association signal of the gene. This SNP-gene
mapping process resulted in 217,637 SNPs mapped to 15,735
protein-coding genes.
2.3 Gene prioritization and evaluation
A gene prioritization framework modified in Sun et al. [19] was
applied. A pre-weighting scheme, preWeight (0.5 to 1.5), to the
seven data sources was originally used to adjust for varying score
ranges across data sources (Supplement Table S1). A higher
preWeight for a platform represents the stronger evidence we
subjectively assigned. To check the robustness of the values given
in preWeight, a second set of preWeight (1 for every platform) was also
tested. We objectively defined the weighting scheme for data
sources (noted as Wi) to weigh their relative magnitude of
evidence. Hence, the prioritization system was applied to search
for the optimal weight matrix. Briefly, we generated a candidate
weight matrix pool consisting of d
N=8
7 weight vectors, where N
represents the number of data sources and d=N+1 represents
possible different weights (i.e. 1 to 8), respectively. The elements in
the weight matrix stand for association, linkage, human gene
expression, human literature search, regulatory pathway, animal
gene expression, and animal literature search, respectively. Each
element in a weight vector represents the strength of information/
evidence for a platform or data source. Then, a combined score
(summation of preWeight6Si6Wi) for each gene could be calculated
by summing over the products of the scores and corresponding
weights from seven data sources. If a gene shows evidence from
multiple data sources, the combined score for such gene would
expect to be higher than a gene only with weak evidence in one or
two data sources given the optimal Wi has been decided.
In the weight matrix selection step, for each weight matrix, all
the 5,055 candidate genes and the core genes were sorted together
by their combined scores. Two parameters, Q (proportion of core
genes) and g (proportion of candidate genes), were introduced to
select weight matrices. Matrices that fulfilled these threshold
criteria were retained (see Text S1) for the next evaluation step.
The depression GWA data was utilized to evaluate the
performance of each retained weight matrix. For each weight
matrix, the p-values distribution of the top j genes (denoted as the
prioritized set) and the randomly selected gene set from the GWA
data with size j (denoted as the random set) were compared using
the Wilcoxon rank-sum test. A significant p-value (p,0.05)
represents that the p-values distribution in the prioritized set is
more significant than in the random set. We generated 1000
random sets in this step for comparisons, and this procedure was
repeated 10 times to obtain standard deviation. For every weight
matrix, a combined score for each gene could be computed based
on the top j ranked prioritized gene set. A cutoff value to choose
DEPgenes was determined by a clear separation of combined
scores distribution between the core genes and the remaining
candidate genes. During these prioritization and evaluation steps,
a number of weight matrices passed our selection criteria as
candidates for the optimal weight matrix.
We applied three approaches to test the robustness of choosing a
specific weight matrix as the optimal one to select for DEPgenes
(Text S2). First, we selected ten weight matrices that passed
selection criteria to evaluate their performance using the GWA
dataset. Second, to investigate whether the rank of prioritized
genes obtained from each weight matrix was similar, pair-wise
Prioritized Candidate Genes Set for Depression
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were calculated using Spearman’s correlation coefficients. A high
correlation on average in these comparisons would demonstrate
the effectiveness and robustness of this prioritization approach.
Third, we investigated the best matrices obtained from our core
gene sets with other two alternative core gene sets for the
robustness of our DEPgenes selection: core gene sets based on best
expression genes and candidate pathway genes. Finally, we
evaluated patterns of gene expression of the DEPgenes and non-
disease genes in human tissues. Non-disease genes were used as the
reference to compare with the DEPgenes. We retrieved human
protein-coding genes and 5,139 disease genes from the GeneCards
database (http://www.genecards.org/) and obtained a total of
15,874 non-disease genes. We then compared the gene expression
patterns between the DEPgenes and non-disease genes in 49
human tissues that were extracted from the WebGestalt Tissue
Expression (http://bioinfo.vanderbilt.edu/webgestalt/) [31] using
Wilcoxon signed-rank test. The proportion of the DEPgenes vs.
non-disease genes expressed in each tissue was computed.
Results
A total of 5,055 depression-related candidate genes were
obtained from seven data sources, including 4,850 genes in
human and 387 genes in animal studies, with only 182 genes
(3.6%=182/5055) overlapping in both species. The percentage of
overlapping genes across data sources was low or moderate; it was
in a range from 0.3 to 24.8% (Supplementary Table S3), which
echoes the challenges we faced to dissect the genetic influences for
depression with commonly seen situations of non-replication and
inconclusive results. Not surprisingly, there were 12.7% (N=60)
overlapping genes between search by human literature (473 genes
identified) and association studies (125 genes identified), indicating
a low redundancy between the two data sources (see Table S3).
In the prioritization procedures, too many weight matrices were
obtained in the nine sets of parameters(Q=0.8, 0.85, 0.9, and g=3,
4, 5%), and we listed only those that met our selection criteria in
Table 1. None of weight matrices passed our selection criteria when
Q equalsto0.8and0.85.Thirteen weight matriceswere reported for
Q=0.9 (one for g=3% and thirteen for g=4 or 5%) in Table 1.
Among them, four matrices, marked in bold, showed better
performance than all others with mean $950; they also had smaller
position j and l, and they were hence considered as candidates for
the optimal weight matrix (definition of j and l is provided in Text
S1). The weight matrix [2,1,1,8,1,1,7] had the highest mean value
of 963.9 (i.e. among 1000 comparisons, there were on average 964
times the selected prioritized gene sets had smaller p-value
distribution than randomly selected gene sets from GWA data). In
addition, the prioritized gene sets obtained by this matrix had high
proportion to exhibit small p-values (,0.05) in the GWA dataset
(Supplementary Figure S1). Thus, we selected matrix [2,1,1,8,1,1,7]
as our final weight matrix for the seven data sources to calculate
combined score for each candidate gene, which equals to (3, 1, 1.5,
4, 1, 1, 3.5) when multiplied the best matrix by preWeight. Notably,
the weights of three data sources (association studies and literature
searches for both human and animal studies) were high, indicating
the evidence from association studies and text-mining was more
informative than that of the other sources.
Toexaminetherobustnessofoptimalweightmatrixselection,nine
other weight matrices were selected with slightly different weight
combinations(alsofitcriteriaofpositionj#200, positionl#2500and
mean $900). All ten matrices showed a very similar pattern in terms
of their p-values distribution of derived prioritized gene sets (see
Supplementary Figure S1). In addition, ranking of prioritized gene
sets generated by the ten matrices were highly correlated with each
other (mean correlation coefficients was 0.92), suggesting that the
DEPgenes selected for depression by the current gene prioritization
system are effective (see Supplementary Table S4). On the contrary,
without the procedure of selecting optimal weight matrix (i.e. use
[1,1,1,1,1,1,1] matrix), the resulting prioritized gene set had poor
performance with low proportion of small p-values (i.e. p,0.05) in
GWA dataset, indicating our weighting scheme for different data
sourcesisstronglyrecommended.Alternatively,wetestedtheoptimal
weight matrices using the best expression and pathway genes as core
gene sets to find alternative sets of optimal weight matrices (see Text
S3). No any matrix passed our matrix selection criteria using
expression core gene set. For pathway core gene set, matrix
[6,2,1,8,7,1,8] was identified as the optimal matrix. Information
extracted from literature search and association studies is high that
wassimilartoresultsfromoriginalcoregeneset.Therewere85genes
overlapped between the DEPgenes and pathway-DEPgenes; 29 out
of 114 pathway-DEPgenes were not included in the original
DEPgenes and the average combined score of these 29 genes (9.39)
was much lower than the cutoff value of 15. These results revealed
comparablefindings from different matrices used and our selection of
DEPgenes is robust.
The distributions of combined scores of the 14 core genes and the
5,055 candidate genes differed (see Supplementary Figure S2), and a
cutoff value of 15 for combined score was chosen to obtain good
discriminability in separating a core gene set from the total candidate
genes to select final DEPgenes. A total of 169 genes whose combined
scores greater than 15 were selected as DEPgenes (see Table 2). The
p-values distribution using the GWA dataset for the 169 DEPgenes
compared with the 5,055 candidate genes is displayed in Figure 1.
The DEPgeneshad significantlyhigherprobability(36.4%) tohave p-
values less than 0.05 than the remaining candidate genes (26.5%)
using Wilcoxon rank-sum test (p=0.00005).
The proportion of genes expressed in 49 human tissues for 169
DEPgenes compared with 15,874 non-disease genes is shown in
Supplementary Figure S3. Ten tissues exhibited expression
differences greater than 4%. Among them, seven tissues were
related to brain or nerve systems, including nervous (13.2%), brain
(11.1%), peripheral nervous system (10.8%), cerebrum (9.2%),
cerebellum (6.6%), eye (6%), and head and neck (4.2%), with the
direction that the DEPgenes tended to express more in brain or
nerve related tissues than non-disease genes.
Discussion
A wealth of genetic data accumulated in the past decade
regarding depression forms a special opportunity to uncover the
biological functions and molecular mechanisms underlying
depression through systematic data collection and integration.
Our approach to prioritize genes according to their evidence in
depression and using combined score to rank candidate genes for
depression not only creates a value-added gene database for
depression, but it also provides a list of candidates for future
exploration of biological functions among these DEPgenes. A few
existing databases have information on susceptible genes for
depression by literature mining or by review of prior publications,
such as HuGE navigator, to serve as a convenient searching
engine. However, without a proper weighting scheme for the
strength of evidence provided from different studies and data
sources, these databases are less informative for follow-up studies.
For instance, in HuGE Navigator (8 Feb 2011 version; http://
www.hugenavigator.net/HuGENavigator/home.do), we searched
gene information for depression and found 690 depression
candidate genes with scores ranged between 0 and 1.5. Using a
Prioritized Candidate Genes Set for Depression
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their scores.0.01. There are 45 out of 104 HuGE depression
genes not in our DEPgenes, with calculated mean combined score
of 6.6 below our cutoff of 15. Some well-known depression
candidate genes that do not have scores greater than 0.01 in the
HuGE genes are included in our DEPgenes, such as DBH,
CHRNA7, and GABRA3, which were all ranked in the top list of
DEPgenes. Without proper evaluation of weighting scheme, using
other search engines may result in omitting important information
for follow-up studies.
The list of the prioritized DEPgenes can be used for individual
replication and to further explore the biological roles of them in
depression using basic science approaches. The top seven
DEPgenes are DBH, BDNF, SLC6A4, NGFR, TNF, GSK3B, and
CHRNA7. The roles of these high-ranking DEPgenes in depression
were supported by review articles and empirical studies. For
instance, increased dopaminergic activity may play a primary role
in depression. Dopamine beta -hydroxylase (DBH) catalyses the
key step in biosynthesis of the neurotransmitter noradrenaline
from dopamine, and low DBH activity from a variety of brain
regions is a possible risk factor for developing depression [32,33].
Serotonin transporter (SLC6A4) and serotonin receptor (HTR1A,
the 13
rd) genes are among the strongest candidates underlying the
etiology of depression [22,34]. A commonly prescribed medication
for treating depression is selective serotonin reuptake inhibitors
(SSRIs) (paroxetine, fluoxetine, sertraline), which acts to keep the
balance in the serotonin neurotransmitter system in the brain [35].
Brain-derived neurotrophic factor (BDNF) is a neuroprotective
Table 1. Selection of the optimal weight matrix by core genes and evaluation by the genome-wide association (GWA) p-values.
Parameter set
a Total number of
weight matrices
Number of weight
matrices met
criteriab Selection by core genes
Selection by GWA p-
values
f
Q (%) g (%) Weight matrix
c Position j
d Positionl
e Mean sd
90 3 4,663 1 [2,1,1,8,1,1,7] 150 1053 966.6 5.4
4 11,916 13 [2,1,1,8,1,1,7] 150 1053 963.9 4.1
[2,1,1,8,1,1,8] 153 738 933.8 5.5
[3,1,1,8,1,1,7] 153 1054 952.6 7.2
[3,1,1,8,1,1,8] 155 738 930.2 9.4
[4,1,1,8,1,1,7] 157 1054 948.2 7.2
` [4,1,1,8,1,1,8] 159 739 922.2 9.3
[5,1,1,8,1,1,7] 157 1054 944.2 4.5
[5,1,1,8,1,1,8] 159 739 928.7 6.5
[6,1,1,8,1,1,7] 159 1054 949.4 8.1
[7,1,1,8,1,1,7] 159 1054 952.4 7.1
[8,1,1,8,1,1,7] 159 1054 955.3 7.5
[7,1,1,6,1,3,7] 159 1159 922.3 12.7
[8,1,1,6,1,3,7] 159 1159 927.4 6.2
5 20,285 13 [2,1,1,8,1,1,7] 150 1053 963.0 5.4
[2,1,1,8,1,1,8] 153 738 931.9 10.5
[3,1,1,8,1,1,7] 153 1054 955.2 8.4
[3,1,1,8,1,1,8] 155 738 931.1 6.5
[4,1,1,8,1,1,7] 157 1054 942.9 9.6
[4,1,1,8,1,1,8] 159 739 925.3 7.4
[5,1,1,8,1,1,7] 157 1054 945.2 9.6
[5,1,1,8,1,1,8] 159 739 925.0 10.6
[6,1,1,8,1,1,7] 159 1054 948.9 4.1
[7,1,1,8,1,1,7] 159 1054 956.0 5.8
[8,1,1,8,1,1,7] 159 1054 951.2 7.9
[7,1,1,6,1,3,7] 159 1159 922.2 8.9
[8,1,1,6,1,3,7] 159 1159 921.7 17.6
Note:
aQ and g denote threshold proportion in the core gene set and the candidate gene set.
bSelection criteria: position j#160, position l#1200 and mean$900. Definition of j and l is shown in footnote d and e below. The weight matrices with mean §950
marked in bold.
cWeight matrix is ordered by vassociation, vlinkage, vexpression_human, vliterature_human, vkegg, vexpression_rat, vliterature_animal.
dPosition j represents the position of the Q-th core gene locates in the g-th top ranked candidate genes.
ePosition l represents the position of the last core gene locates in the ranked candidate genes.
fMean: total number of random subsets having significant different p-value distribution from the top ranked candidate genes (Wilcoxon rank-sum test, p,0.05); sd:
standard deviation.
doi:10.1371/journal.pone.0018696.t001
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responses to stress by preventing hippocampal cells from damage
and is suggested to be associated with depression [23,36]. The
nerve growth factor receptor (NGFR) encodes the affinity and
modulates the activity of tyrosine kinases for neurotrophin family,
and plays a potential role in ligand binding and signaling. The
NGFR was reported to have protective effect against the
development of depressive disorder [37]. The tumor necrosis
factor (TNF) plays roles in altering neural-immune interactions,
including levels of proinflammatory cytokines, increased pain
sensitivity and elevated inflammatory activity [38]. Prior evidence
supports that the development of depression is related to the levels
of proinflammatory cytokines TNF-a and to interleukin-6 (IL6, the
33
rd) in the brain [38–40]. Glycogen synthase kinase 3 beta
(GSK3B) is an enzyme involved in energy metabolism and
neuronal cell development, which are processes related to
depression [36]. The GSK3B plays an important role in the action
of mood stabilizer [41]. Lastly, the a7 neuronal nicotinic
acetylcholine receptor subunit gene (CHRNA7) is a cholinergic
receptor, which has been reported to be associated with a sensory
deficit in common mental illness [42] and neurochemical changes
in depression-like behavior [43]. Comparison of gene expression
patterns of the DEPgenes with non-disease genes in human tissues
exhibited high expression proportion among the DEPgenes in
human brain or nerve related tissues. This is in accordance to the
neurotransmitter action, which refers to the chemical message to
influence intellectual functioning and behavior, and theories of
neuroplasticity, which refers to the ability of learning to change
through experience in human brain. Both expressions have been
suggested to underlie the risk for depression [44].
Table 2. The 169 DEPgenes with combined score$15.
Gene
Combined
score Gene
Combined
score Gene
Combined
score Gene
Combined
score Gene
Combined
score
DBH 47.74 TPH2 28.50 NOS1 21.94 ANXA2 18.07 TSNAX 16.41
BDNF 46.52 CRH 28.03 PRKACA 21.93 GNB3 18.04 TFCP2 16.39
SLC6A4 46.29 ACCN2 27.79 GFAP 21.87 ADRB1 18.03 CYP2C19 16.39
NGFR 46.04 ESR1 27.67 IL1B 21.86 POMC 18.01 GRIA1 16.36
TNF 43.61 ACSL4 27.58 HTR2C 21.72 NOS3 18.00 FMR1 16.35
GSK3B 40.25 SLC6A3 27.20 TH 21.42 D2S2944 18.00 SLC5A4 16.32
CHRNA7 40.24 SLC6A2 26.99 CYP1A1 21.33 DXS7 18.00 CC2D1A 16.32
GABRA3 37.55 ADRA2A 26.87 HTR5A 21.00 GABRA5 18.00 GLI2 16.30
CYP2C9 37.33 CNR1 26.64 SMPD1 20.97 LBP 18.00 CAT 16.29
NTRK3 37.17 NQO1 26.41 APAF1 20.79 M6PR 18.00 L1CAM 16.28
ADCY7 36.13 AVPR1B 26.30 TSPO 20.57 MAMDC1 18.00 CDH17 16.27
PDLIM5 35.99 TACR1 26.16 GNAL 20.48 MCP1 18.00 DNAJB1 16.27
HTR1A 35.50 GAD2 26.12 GMIP 20.29 PDE11A 18.00 CD3E 16.22
P2RX7 35.39 TAAR6 26.00 TOR1A 20.23 SLC5A7 18.00 MTHFR 16.19
HTR2A 35.29 TPH1 25.81 CCKAR 20.10 VMAT2 18.00 VEGFA 16.18
CCL2 35.24 HTR3A 25.77 CTLA4 20.00 ABCB1 17.89 DNMT3B 16.15
PDE9A 34.90 GABRA1 25.67 ADCYAP1 20.00 PDYN 17.71 AKT1 16.14
DAOA 34.00 ESR2 25.61 CYP1A2 19.89 SAT1 17.35 SERPINE1 16.13
NPY 33.68 COMT 25.55 GNAS 19.88 S100B 17.34 HSPA12A 16.13
GRIN1 33.44 PLA2G2A 25.53 FKBP5 19.61 CD63 17.14 S100A10 16.11
CHRM2 33.25 GAD1 25.51 GDNF 19.50 GABRA6 17.12 CYP2D6 16.07
NR3C1 32.95 DTNBP1 25.00 PLA2G4A 19.42 ALDH1A1 17.03 GABRA2 16.03
DRD4 32.77 ACE 24.14 ADRA1A 19.17 RELN 17.00 PTX3 16.00
CREB1 32.54 XBP1 23.41 SLC1A4 18.88 ATP6V1B2 16.87 C5orf20 16.00
DRD3 32.31 MAOB 23.36 HSPA1A 18.83 CAMK2A 16.68 GHRL 16.00
CRHR2 31.97 P2RX4 23.35 CACNA1C 18.52 BCR 16.58 IVNS1ABP 16.00
CRHR1 31.36 APOE 23.11 GRIK3 18.45 HTT 16.56 PDSS1 16.00
AR 30.79 WFS1 23.03 AGTR1 18.27 CLOCK 16.56 GAL 15.86
DRD1 30.63 IL10 22.88 PDE1A 18.24 GRIN2B 16.56 AGT 15.78
PLXNA2 30.09 DRD2 22.63 CHRNA5 18.20 PCLO 16.53 TAC1 15.75
MAOA 29.57 DISC1 22.59 CPLX2 18.20 NRG1 16.50 NTRK2 15.68
OPRM1 29.30 PDE4B 22.59 HTR6 18.15 QKI 16.47 SLC6A1 15.56
IL6 29.06 CRHBP 22.19 CCK 18.12 GRIN2A 16.42 CTNNB1 15.18
HTR1B 28.99 PDE5A 22.00 ARRB2 18.10 DIO2 16.42
doi:10.1371/journal.pone.0018696.t002
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human genes were identified as susceptible genes for depression in
one or several data sources. The candidate genes for depression
across data sources had low overlap. This is partly reflected by
poor replications across study designs and species in prior
individual genetic studies. Several reasons may explain such
observation, including heterogeneity of the depression phenotype,
different study designs, lack of power in some studies, interaction
of genetic and environmental factors, publication bias, and false-
positive findings in most of the candidate gene studies [45].
The idea of using preWeight is to adjust for prior information/
evidence imbalance across multidimensional data sources. If our
results of genes ranking are robust, the list of DEPgenes should be
similar with or without preWeight adjustment, and this is indeed
what we observed. If preWeight was not applied, weight matrix
[6,1,4,8,4,2,8] had the best performance and the corresponding
prioritized genes set was very similar to those obtained using
preWeight (data not shown). It is also worth noting that the weights
for human and animal literature search were high regardless of
using preWeight or not. This implicated that text-mining with
efficient algorithm may exhibit a useful strategy to quickly discover
the relationship between diseases and genes with less bias [19,46].
The optimal weight matrix selection was based on two datasets
in the current framework: a set of core genes through expert
review and an independent GWA depression dataset. Previously
suggested candidate genes from meta-analysis or review articles
are still few, thus limiting the number of genes to be included in
the core gene set. Having a representative core gene set of
depression is essential to the final gene selection, as the numbers of
weight matrices that satisfied the selection criteria were correlated
with setting threshold of Q (proportion of core genes). Setting
larger Q may assist to better identify an optimal weight matrix. It is
possible that with an increasing number of core genes, we can
allow the threshold to be lower. For the GWA dataset, although
there were a few published GWA studies for depression
[7,9,10,17], only the GAIN dataset was deposited in a public
repository and is freely available through an application process. If
other GWA datasets could be acquired, the prioritization process
can be cross validated by different GWA data to increase the
precision and predictability in the current study, such that one
GWA dataset can be used in random set comparison process and
another GWA dataset can be used in p-value evaluation process,
and so on. In sum, our selection of DEPgenes not only adopted
proper weighting from multiple data sources, but also incorporat-
ed information from biological pathways. More exploratory and
advanced pathway/network analyses can be conducted to further
provide useful information from the created DEPgenes list. Similar
data prioritization and evaluation procedures were used in other
neuropsychiatric disorders, such as schizophrenia [19]. Sun et al.,
identified a list of schizophrenia candidate genes and successfully
constructed pathways and networks among those genes [47].
Pathways overrepresented in their selected schizophrenia candi-
date genes were related to neurodevelopment and immune system.
This is encouraging to conduct future work using system biological
approach in the DEPgenes.
This study has some limitations. First, the choice of core genes
was knowledge-based and subjective, which may influence the
optimal weight matrix selection and the resulting DEPgenes.
Nevertheless, our evaluations using different qualified weight
matrices and alternative core gene sets found very similar list of
DEPgenes with high correlation across weight matrices and
comparable results from alternative pathway core gene set.
Second, one may concern that larger genes were easier to be
picked up by DEPgenes due to the bias of significant p-values
towards gene length. In the GWA GAIN-MDD data, we observed
a positive relationship between smaller p-values and larger genes
among all human genes. However, there is no difference between
the proportion of larger gene size (say .10000 kb) in the
Figure 1. Comparisons of p-values distribution using the GAIN GWA-depression data for the 169 prioritized DEPgenes and the
remaining candidate genes (N=4886).
doi:10.1371/journal.pone.0018696.g001
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value=0.47) and resulting random selected gene sets, which
indicated that our selection of DEPgenes is unlikely impacted by
the bias toward long gene length. Third, some of the candidate
genes might be falsely reported in the literature as significant
markers for depression and falsely collected as candidates,
potentially providing incorrect evidence in our study. Similarly,
while the phenotype of interest is depression, different studies may
apply different measures and construct regarding ‘‘depression’’,
which may cause unavoidable noise in the evaluation process.
Lastly, only human and available mouse data were considered in
the current study. With increased data and knowledge accumu-
lation in the near future, an updated and more precise DEPgenes
list can be provided.
To our knowledge, this is the first comprehensive evidence-
based candidate gene resource for depression. We expect the
identification of potential susceptibility genes for depression will
facilitate etiology and mechanism-related research. Through a
systems biology view, new data generated by high-throughput
genomics, proteomics or other relevant data sources could be
utilized to extend the current dimensions of data collection,
providing researchers an opportunity to implement pathway- or
network-based analysis to explore the underlying functional
correlation among susceptible genes of depression in the near
future.
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